0001140361-15-037232.txt : 20151008 0001140361-15-037232.hdr.sgml : 20151008 20151008174531 ACCESSION NUMBER: 0001140361-15-037232 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20151006 FILED AS OF DATE: 20151008 DATE AS OF CHANGE: 20151008 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9143477000 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sanofi CENTRAL INDEX KEY: 0001121404 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] STATE OF INCORPORATION: I0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19034 FILM NUMBER: 151151578 BUSINESS ADDRESS: STREET 1: 54 RUE LA BOETIE CITY: PARIS STATE: I0 ZIP: 75008 BUSINESS PHONE: 33153774400 MAIL ADDRESS: STREET 1: 54 RUE LA BOETIE CITY: PARIS STATE: I0 ZIP: 75008 FORMER NAME: FORMER CONFORMED NAME: SANOFI-AVENTIS DATE OF NAME CHANGE: 20040826 FORMER NAME: FORMER CONFORMED NAME: SANOFI SYNTHELABO SA DATE OF NAME CHANGE: 20010104 4 1 doc1.xml FORM 4 X0306 4 2015-10-06 0 0000872589 REGENERON PHARMACEUTICALS INC REGN 0001121404 Sanofi 54, RUE LA BOETIE PARIS I0 75008 FRANCE 0 0 1 0 Common Stock 2015-10-06 4 P 0 1107 449.1383 A 23018099 I See note Common Stock 2015-10-06 4 P 0 1200 450.2306 A 23019299 I See note Common Stock 2015-10-06 4 P 0 1451 451.3084 A 23020750 I See note Common Stock 2015-10-06 4 P 0 1768 452.3727 A 23022518 I See note Common Stock 2015-10-06 4 P 0 3842 453.4794 A 23026360 I See note Common Stock 2015-10-06 4 P 0 4140 454.4757 A 23030500 I See note Common Stock 2015-10-06 4 P 0 3601 455.5580 A 23034101 I See note Common Stock 2015-10-06 4 P 0 2480 456.5556 A 23036581 I See note Common Stock 2015-10-06 4 P 0 2938 457.6022 A 23039519 I See note Common Stock 2015-10-06 4 P 0 9730 458.5797 A 23049249 I See note Common Stock 2015-10-06 4 P 0 6697 459.5495 A 23055946 I See note Common Stock 2015-10-06 4 P 0 12798 460.7054 A 23068744 I See note Common Stock 2015-10-06 4 P 0 9271 461.6131 A 23078015 I See note Common Stock 2015-10-06 4 P 0 5411 462.6074 A 23083426 I See note Common Stock 2015-10-06 4 P 0 5812 463.7103 A 23089238 I See note Common Stock 2015-10-06 4 P 0 1190 464.5745 A 23090428 I See note Common Stock 2015-10-06 4 P 0 900 466.0381 A 23091328 I See note Common Stock 2015-10-06 4 P 0 2200 467.3464 A 23093528 I See note Common Stock 2015-10-06 4 P 0 1702 468.4879 A 23095230 I See note Common Stock 2015-10-06 4 P 0 2300 469.4610 A 23097530 I See note The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). Purchase prices range from $448.70 to $449.50 per share, inclusive. Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,297,978 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Purchase prices range from $449.94 to $450.73 per share, inclusive. Purchase prices range from $450.99 to $451.94 per share, inclusive. Purchase prices range from $452.00 to $452.96 per share, inclusive. Purchase prices range from $453.02 to $454.01 per share, inclusive. Purchase prices range from $454.03 to $454.92 per share, inclusive. Purchase prices range from $455.04 to $456.03 per share, inclusive. Purchase prices range from $456.10 to $457.07 per share, inclusive. Purchase prices range from $457.10 to $458.03 per share, inclusive. Purchase prices range from $458.10 to $459.09 per share, inclusive. Purchase prices range from $459.10 to $460.08 per share, inclusive. Purchase prices range from $460.13 to $461.12 per share, inclusive. Purchase prices range from $461.13 to $462.08 per share, inclusive. Purchase prices range from $462.13 to $463.11 per share, inclusive. Purchase prices range from $463.15 to $464.10 per share, inclusive. Purchase prices range from $464.32 to $465.00 per share, inclusive. Purchase prices range from $465.78 to $466.28 per share, inclusive. Purchase prices range from $466.89 to $467.79 per share, inclusive. Purchase prices range from $467.91 to $468.80 per share, inclusive. Purchase prices range from $468.98 to $469.74 per share, inclusive. Due to technical limitation of the number of transactions reported, this report is 1 of 2. /s/ John Felitti, Associate Vice President, Corporate Law, Financial & Securities Law 2015-10-08